View ValuationDIAGNOS 将来の成長Future 基準チェック /06現在、 DIAGNOSの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare Services 収益成長22.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Aug 04DIAGNOS Inc., Annual General Meeting, Sep 30, 2026DIAGNOS Inc., Annual General Meeting, Sep 30, 2026. Location: quebec, brossard, CanadaNew Risk • Jul 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.8m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (CA$65k revenue, or US$46k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€18.0m market cap, or US$20.5m).お知らせ • Jul 28Diagnos Inc. Receives Health Canada Medical Device Licence for CARA SystemDiagnos Inc. has received a Health Canada Medical Device Licence authorizing the commercialization of its CARA System in Canada. CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow: CARA-AMDdetect – Age-related macular degeneration detection, CARA-DR – Diabetic retinopathy detection, CARA-MVA – Retinal microvascular analysis, CARA-Enhancement – Advanced retinal image enhancement, CARA-CWS - Clinician WorkSpace for annotations. By combining image enhancement, explainable AI findings, fundus indicators and retinal vascular analytics, CARA helps clinicians unlock more clinically relevant information from every fundus photograph while ensuring that the optometrist remains in full control of every clinical decision. CARA is one the first Canadian AI-retinal image analysis platform developed specifically for the Optometry sector to be granted a Class II medical device licence by Health Canada. This authorization allows us to fully deliver our services to IRIS The Visual Group (refer to announcement dated June 7, 2022) and to deploy our marketing strategy to address the Canadian optometry market. Retina of the eye photography is routinely incorporated into optometry clinical workflows practices from both independent optometry practices and major eye care networks. Using advanced image enhancement and explainable artificial intelligence, CARA System uses every pixel of a fundus photograph to provide the optometrist with objective analytical insights related to retinal conditions that may not have been readily apparent. CARA System is by nature a medical device which, in most markets, requires proper local regulatory commercialization authorization. Meeting regulatory compliance for medical devices ensures public safety. Management focus remains obtaining regulatory commercialization clearance for CARA System from the Saudi Arabia Food & Drug Authority (SFDA) and the United States Food and Drug Administration (US-FDA). Saudi Arabia: As stated in the Management Discussion and Analysis report (MD&A) dated June 11, 2026, available on www.diagnos.com and www.sedarplus.com, Diagnos formally submitted CARA System for marketing approval with the SFDA. Since then, the Corporation is addressing additional queries received from the SFDA. USA: As stated in MD&A dated June 11, 2026, available on www.diagnos.com and www.sedarplus.com, the legacy version of CARA, as a Medical Image Management and Processing System, remains cleared for commercialization in the U.S. With the help of our U.S. based regulatory consultant, our goal is to be able to submit the commercialization application of CARA System to the FDA before the end of September 2026.お知らせ • Jun 16Diagnos Inc Submits Modified And Updated Health Canada Licence Application For Cara System PlatformDiagnos Inc. submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada. Following detailed guidance from Health Canada in the fall of 2025, the Corporation's collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to revolutionize how optometrists view, analyze, and interpret fundus photography. In integrating image enhancement and an interpretability tool directly into the clinical workflow, CARA delivers detailed analytical insights that support clinical findings during comprehensive examinations, ensuring practitioners always remain the final authority on patient care. CARA System includes CARA-Enhancement, CARA-AM detect, CARA-DR and CARA-MVA. In this submission the company will make an exception in stating that the Corporation has strictly followed the frameworks and guidance provided by Health Canada.Reported Earnings • Jun 12Full year 2026 earnings released: CA$0.042 loss per share (vs CA$0.049 loss in FY 2025)Full year 2026 results: CA$0.042 loss per share. Net loss: CA$4.56m (loss widened 6.3% from FY 2025).New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.8m free cash flow). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (CA$68k revenue, or US$49k). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€16.5m market cap, or US$19.2m).Board Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. 1 highly experienced director. CEO, President & Executive Director Andre Larente is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 02Diagnos Inc Successfully Completes Renewal Of US-FDA Medical Device Establishment RegistrationDiagnos Inc. had completed the annual registration for its medical device establishment with the U.S. Food and Drug Administration (FDA). Additionally, DIAGNOS would like to remind the reader that the legacy version of CARA, as a Medical Image Management and Processing System, remains cleared for commercialization in the USA. The future version of CARA, which incorporates many other eye-related disease detection algorithms, is in the process of obtaining applicable regulatory approvals as detailed in the press release dated January 13, 2026.お知らせ • Jan 14Diagnos Inc. Advances Regulatory Strategy for Cara in Key Markets: Updates on Health Canada, Fda, and Sfda ProgressDiagnos Inc. provided an update on the regulatory pathway for its AI platform, CARA. This follows the acceleration plan announced on October 8, 2025. The Corporation continues to execute its strategy to secure approvals in three targeted jurisdictions: Saudi Arabia (SFDA): DIAGNOS has formally submitted CARA for marketing approval to the Saudi Food and Drug Authority (SFDA). Canada (Health Canada): The Corporation is actively engaged with Health Canada to ensure full alignment with applicable medical device regulations. DIAGNOS confirms it is on track to submit its formal application for CARA in the course of this current quarter. United States (FDA): Following strategic meetings with the U.S. Food & Drug Administration (FDA), DIAGNOS has clarified the specific requirements to secure 510(k) clearance, paving the way for commercialization in the US market.お知らせ • Dec 10DIAGNOS Inc. announced that it has received CAD 4.001179 million in fundingOn December 9, 2025, DIAGNOS Inc. closed the transaction. The company announced that it has issued 13,337,262 Units at a price of CAD 0.30 per Unit for aggregate gross proceeds of CAD 4,001,178.60. The transaction is oversubscribed. In connection with the Offering, the Company paid a cash commission of CAD 153,974.40, issued 666,863 Units as a corporate finance fee and issued 513,248 broker warrants (the “Broker Warrants”). Each Broker Warrant entitles the holder to acquire a Unit at the Issue Price at any time on or before June 6, 2027. The securities to be issued under the Offering will have a hold period of four months and one day from the Closing Date under applicable Canadian securities laws. Certain related parties of the Company, namely two (2) directors and one (1) officer, participated in the Offering, acquiring an aggregate of 316,665 Units on the same basis as other subscribers. The transaction is oversubscribed.お知らせ • Nov 11DIAGNOS Inc. announced that it expects to receive CAD 2 million in fundingDIAGNOS Inc. announces a brokered private placement to issue 6,666,667 units at a price of CAD 0.30 per unit for gross proceeds of CAD 2,000,000.1 on November 10, 2025. Each Unit shall consist of one common share in the capital of the Company and one common share purchase warrant. Each Warrant shall be exercisable into one additional common share of the Company at a price of CAD 0.40 per Warrant Share at any time for a period of 18 months following the Closing Date. The Offering is expected to close on or around December 3, 2025, or such other dates as agreed upon between the Company and the Lead Agent and is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the Offering will have a hold period of four months and one day from the Closing Date under applicable Canadian securities laws.お知らせ • Nov 01Diagnos Inc. Announces the Appointment of Dr. Philipgpe Couillard as Chairman of the Board of DirectorsDiagnos Inc. announced the appointment of Dr. Philipgpe Couillard as Chairman of the board of directors (the “Board”).Dr. Couillard is a seasoned business advisor and neurosurgeon. He has served in two significant public roles in the government of the province of Quebec (Canada); as Minister of Health and Social Services between 2003 and 2008 and as Premier of the province from 2014 to 2018. Dr. Couillard joined the Board of DIAGNOS on April 1, 2024.お知らせ • Oct 28DIAGNOS Inc. Announces Dr. Pierre-Luc Charlebois Joins Advisory BoardDIAGNOS Inc. announced that Dr. Pierre-Luc Charlebois has joined the Corporation’s Advisory Board. Along with fellow members, Dr. Tomas J. Philipson, former vice chairman of the White House Council of Economic Advisers, Mr. Ed Weiner, a seasoned entrepreneur, and Dr. Barry A. Ginsberg, optometrist, Dr. Charlebois will act as special counsel to the Corporation’s management. Dr. Charlebois is an orthopedic surgeon practicing in the province of Quebec, Canada. Dr. Charlebois earned his orthopedic surgeon medical degree from the University of Montreal. He also holds a master`s degree in Health Economics, Policy and Management from the London School of Economics and Political Science.お知らせ • Sep 06DIAGNOS Inc. announced that it has received CAD 0.1 million in fundingOn September 5, 2025, DIAGNOS Inc. closed the transaction. The company issued 10 units at a price of CAD 10,000 per unit for gross proceeds of CAD 100,000. Each unit consists of one CAD 10,000 unsecured convertible debenture and 10,000 stock warrants. The units have been subscribed by one director of the corporation. Each debenture has a term of 12 months and bears interest at the annual rate of 10%, payable in cash. At the option of the holder of the debenture, the principal amount may be converted, at any time during the term, into common shares of the corporation at a price of CAD 0.28 per share. Each warrant entitles the holder to purchase one share at a price of CAD 0.40 per share, at any time during the term. All securities to be issued as part of the private placement are subject to a statutory hold period ending on January 6, 2026. The private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation.お知らせ • Sep 04DIAGNOS Inc. announced that it expects to receive CAD 0.1 million in fundingDIAGNOS Inc. announces a non-brokered private placement to issue 10 units at a price of CAD 10,000 per unit for gross proceeds of CAD 100,000 on September 3, 2025. Each unit consists of One CAD 10,000 unsecured convertible debenture and 10,000 stock warrants. Each Debenture has a term of 12 months and bears interest at the annual rate of 10%, payable in cash. At the option of the holder of the Debenture, the principal amount may be converted, at any time during the Term, into common shares of the Corporation at a price of CAD 0.28 per Share. One director of the Corporation has committed to subscribe for all of the Units of the Private placement. All securities to be issued as part of the Private placement will be subject to a 4-month statutory hold period. The Private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation.お知らせ • Jul 28DIAGNOS Inc., Annual General Meeting, Sep 25, 2025DIAGNOS Inc., Annual General Meeting, Sep 25, 2025. Location: quebec, brossard Canadaお知らせ • Jun 26DIAGNOS Inc. Announces Dr. Barry A. Ginsberg Joins Advisory BoardDiagnos Inc. announced that Dr. Barry A. Ginsberg, O.D. has joined the Corporation's Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers and Mr. Ed Weiner, a seasoned entrepreneur, to provide valuable insights to DIAGNOS about the US optical market. Dr. Ginsberg brings more than three decades of practice across corporate, retail and private-practice settings, giving him a ground-level view of how new technologies gain traction in high-volume optometry environments. He has repeatedly identified and launched innovative products and services that increased revenue per visit and improved patient retention for leading optical chains. This commercial experience, combined with his expertise in advanced contact-lens fitting and ocular-disease management, will help DIAGNOS refine its go-to-market strategy and demonstrate the tangible ROI of AI-driven screening to investors and practitioners alike. Dr. Ginsberg earned a B.A. in Chemistry with a minor in Economics from Yeshiva University, followed by a B.S. and Doctor of Optometry from the Pennsylvania College of Optometry. His training included an externship at the Feinbloom Low Vision Center in Philadelphia, where he focused on age-related macular degeneration, and another at the Goldschleger Eye Institute in Tel Hashomer Hospital, Israel, where he concentrated on glaucoma and other ocular diseases.お知らせ • Jun 11Diagnos Appoints Ed Weiner, to Its Advisory Board for the United StatesDiagnos Inc. announced that Mr. Ed Weiner has joined the Corporation’s Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers, to provide valuable insights to DIAGNOS about the US optical market. Mr. Weiner is a seasoned entrepreneur and has been a leader in the optical industry for decades. He was the first to introduce Ralph Lauren Eyewear. He also partnered with Walmart to open 400 optical locations within Walmart’s chain of stores. Mr. Weiner was also chairman and founder of National Vision Associates, one of the largest optical retailers in the USA.お知らせ • Jun 05Diagnos Inc. Announces That Tomas J. Philipson Joins the Corporation's Advisory BoardDiagnos Inc. announced that Dr. Tomas J. Philipson has joined the Corporation’s Advisory Board. Dr. Tomas J. Philipson is considered an expert in US economic policy, particularly health care policy and appears often on major media outlets, including Forbes, The Economist, The Wall Street Journal, The New York Times, CNN, BBC, CBS, ABC, CNBC, Fox News, Fox Business, Newsmax, Yahoo Finance, American Voice, Bloomberg, and CSPAN. He currently serves as Managing Partner of the VC firm MEDA Ventures, serves on several corporate boards, and has co-founded several companies, including Precision Health Economics LLC, with an exit in 2015 (currently owned by Blackstone). His government service includes a full-time position as vice chairman and acting chairman of the White House Council of Economic Advisers 2017-20. He previously served as a senior economic adviser to the head of the Food and Drug Administration (FDA) and a senior economic advisor to the head of the Centers for Medicare and Medicaid Services (CMS). Dr. Philipson was appointed to the Key Indicator Commission by the Speaker of the House of Representatives in 2012. He was a scientific advisor to the House of Representatives initiative 21st Century Cures in 2015 and The Biden Cancer Initiative in 2017. He served as a healthcare advisor to Senator John McCain's 2008 presidential campaign. He received numerous worldwide research awards while he was a chaired professor at the University of Chicago. He is a two-time winner of the Arrow Award of The International Health Economics Association, the highest honor in health economics. Other awards include the Garfield Award for Economic Research, the Prêmio Haralambos Simeonidis from the Brazilian Economic Association, and the Milken Institute’s Distinguished Economic Research Award. He received a B.A. in mathematics from Uppsala University in Sweden, an MA in Mathematics from Claremont Graduate School, and an MA and Ph.D. in Economics from the Wharton School and the University of Pennsylvania.お知らせ • Apr 09Diagnos Inc. Provides Update on its Health Canada Medical Device License ApplicationDIAGNOS Inc. provided an update on the progress of its Medical device license application for CARA System, submitted to Health Canada in early September 2024. Following the submission of its application in early September, DIAGNOS has engaged in ongoing communication with Health Canada, providing timely responses to all regulatory requests. After more than 11 proactive inquiries regarding the application's status, the company announced that Health Canada has confirmed that the application is now under "active processing", having progressed from a previous backlog.お知らせ • Feb 26DIAGNOS Inc. to File for FDA Pre-Market Authorization of Its AI-Powered Cara SystemDiagnos Inc. announced that it is officially filing for U.S. Food and Drug Administration (FDA) pre-market authorization of its CARA SYSTEM, a machine-learning-enabled medical device (MLMD). To ensure a smooth regulatory process, DIAGNOS has engaged ORA, a leading clinical research organization specializing in regulatory affairs and clinical development for ophthalmic products. The CARA SYSTEM is designed to assist optometrists and frontline healthcare professionals in analyzing fundus images for the early detection of diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy. By leveraging Artificial Intelligence, DIAGNOS aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.お知らせ • Feb 06DIAGNOS Inc. announced that it has received CAD 2.014611 million in fundingDIAGNOS Inc. announced a non-brokered private placement to issue 6,715,370 units at a price of CAD 0.30 per unit for gross proceeds of CAD 2,014,611 on February 5, 2025. Each Unit consists of one common share and one common share warrant. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending August 5, 2026. In connection with the closing of the Private Placement, the Corporation paid cash commissions totaling CAD 39,246.72 and issued an aggregate number of 130,821 finder’s warrants to five qualified firms acting at arm’s length to the Corporation. Each finder’s warrant entitles the holder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending August 5, 2026. All securities issued as part of the Private Placement are subject to a statutory hold period ending June 6, 2025. The closing of the Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、DIAGNOS は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:4D4A - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20260-5-4-4N/A12/31/20250-5-4-4N/A9/30/20250-5-4-4N/A6/30/20250-5-4-4N/A3/31/20250-4-4-4N/A12/31/20240-4-3-3N/A9/30/20240-3-2-2N/A6/30/20240-3-2-2N/A3/31/20240-3-2-2N/A12/31/20230-3-2-2N/A9/30/20230-3-2-2N/A6/30/20230-3-2-2N/A3/31/20230-2-2-2N/A12/31/20221-2-2-2N/A9/30/20221-3-2-2N/A6/30/20221-3-2-2N/A3/31/20220-3-2-2N/A12/31/20210-3-2-2N/A9/30/20210-2-2-2N/A6/30/20210-2-2-2N/A3/31/20210-2-1-1N/A12/31/20200-3-2-2N/A9/30/20200-3-2-2N/A6/30/20200-3-2-2N/A3/31/20200-3-3-3N/A12/31/20190-3N/A-2N/A9/30/20190-3N/A-2N/A6/30/20190-4N/A-3N/A3/31/20190-4N/A-2N/A12/31/20180-4N/A-3N/A9/30/20181-4N/A-2N/A6/30/20181-3N/A-1N/A3/31/20181-4N/A-2N/A12/31/20172-4N/A-2N/A9/30/20172-3N/A-2N/A6/30/20172-4N/A-2N/A3/31/20172-3N/A-2N/A12/31/20161-2N/A-1N/A9/30/20160-3N/A-2N/A6/30/20161-3N/A-2N/A3/31/20161-3N/A-2N/A12/31/20151-3N/A-2N/A9/30/20151-3N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4D4Aの予測収益成長が 貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4D4Aの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4D4Aの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4D4Aの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4D4Aの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4D4Aの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/06 19:18終値2026/08/06 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DIAGNOS Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Stefan QuennevilleVentum Financial Corp
お知らせ • Aug 04DIAGNOS Inc., Annual General Meeting, Sep 30, 2026DIAGNOS Inc., Annual General Meeting, Sep 30, 2026. Location: quebec, brossard, Canada
New Risk • Jul 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.8m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (CA$65k revenue, or US$46k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€18.0m market cap, or US$20.5m).
お知らせ • Jul 28Diagnos Inc. Receives Health Canada Medical Device Licence for CARA SystemDiagnos Inc. has received a Health Canada Medical Device Licence authorizing the commercialization of its CARA System in Canada. CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow: CARA-AMDdetect – Age-related macular degeneration detection, CARA-DR – Diabetic retinopathy detection, CARA-MVA – Retinal microvascular analysis, CARA-Enhancement – Advanced retinal image enhancement, CARA-CWS - Clinician WorkSpace for annotations. By combining image enhancement, explainable AI findings, fundus indicators and retinal vascular analytics, CARA helps clinicians unlock more clinically relevant information from every fundus photograph while ensuring that the optometrist remains in full control of every clinical decision. CARA is one the first Canadian AI-retinal image analysis platform developed specifically for the Optometry sector to be granted a Class II medical device licence by Health Canada. This authorization allows us to fully deliver our services to IRIS The Visual Group (refer to announcement dated June 7, 2022) and to deploy our marketing strategy to address the Canadian optometry market. Retina of the eye photography is routinely incorporated into optometry clinical workflows practices from both independent optometry practices and major eye care networks. Using advanced image enhancement and explainable artificial intelligence, CARA System uses every pixel of a fundus photograph to provide the optometrist with objective analytical insights related to retinal conditions that may not have been readily apparent. CARA System is by nature a medical device which, in most markets, requires proper local regulatory commercialization authorization. Meeting regulatory compliance for medical devices ensures public safety. Management focus remains obtaining regulatory commercialization clearance for CARA System from the Saudi Arabia Food & Drug Authority (SFDA) and the United States Food and Drug Administration (US-FDA). Saudi Arabia: As stated in the Management Discussion and Analysis report (MD&A) dated June 11, 2026, available on www.diagnos.com and www.sedarplus.com, Diagnos formally submitted CARA System for marketing approval with the SFDA. Since then, the Corporation is addressing additional queries received from the SFDA. USA: As stated in MD&A dated June 11, 2026, available on www.diagnos.com and www.sedarplus.com, the legacy version of CARA, as a Medical Image Management and Processing System, remains cleared for commercialization in the U.S. With the help of our U.S. based regulatory consultant, our goal is to be able to submit the commercialization application of CARA System to the FDA before the end of September 2026.
お知らせ • Jun 16Diagnos Inc Submits Modified And Updated Health Canada Licence Application For Cara System PlatformDiagnos Inc. submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada. Following detailed guidance from Health Canada in the fall of 2025, the Corporation's collaborative interactions have resulted in a comprehensive, advanced image analysis platform. The CARA System is designed to revolutionize how optometrists view, analyze, and interpret fundus photography. In integrating image enhancement and an interpretability tool directly into the clinical workflow, CARA delivers detailed analytical insights that support clinical findings during comprehensive examinations, ensuring practitioners always remain the final authority on patient care. CARA System includes CARA-Enhancement, CARA-AM detect, CARA-DR and CARA-MVA. In this submission the company will make an exception in stating that the Corporation has strictly followed the frameworks and guidance provided by Health Canada.
Reported Earnings • Jun 12Full year 2026 earnings released: CA$0.042 loss per share (vs CA$0.049 loss in FY 2025)Full year 2026 results: CA$0.042 loss per share. Net loss: CA$4.56m (loss widened 6.3% from FY 2025).
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.8m free cash flow). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (CA$68k revenue, or US$49k). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€16.5m market cap, or US$19.2m).
Board Change • May 20High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. 1 highly experienced director. CEO, President & Executive Director Andre Larente is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 02Diagnos Inc Successfully Completes Renewal Of US-FDA Medical Device Establishment RegistrationDiagnos Inc. had completed the annual registration for its medical device establishment with the U.S. Food and Drug Administration (FDA). Additionally, DIAGNOS would like to remind the reader that the legacy version of CARA, as a Medical Image Management and Processing System, remains cleared for commercialization in the USA. The future version of CARA, which incorporates many other eye-related disease detection algorithms, is in the process of obtaining applicable regulatory approvals as detailed in the press release dated January 13, 2026.
お知らせ • Jan 14Diagnos Inc. Advances Regulatory Strategy for Cara in Key Markets: Updates on Health Canada, Fda, and Sfda ProgressDiagnos Inc. provided an update on the regulatory pathway for its AI platform, CARA. This follows the acceleration plan announced on October 8, 2025. The Corporation continues to execute its strategy to secure approvals in three targeted jurisdictions: Saudi Arabia (SFDA): DIAGNOS has formally submitted CARA for marketing approval to the Saudi Food and Drug Authority (SFDA). Canada (Health Canada): The Corporation is actively engaged with Health Canada to ensure full alignment with applicable medical device regulations. DIAGNOS confirms it is on track to submit its formal application for CARA in the course of this current quarter. United States (FDA): Following strategic meetings with the U.S. Food & Drug Administration (FDA), DIAGNOS has clarified the specific requirements to secure 510(k) clearance, paving the way for commercialization in the US market.
お知らせ • Dec 10DIAGNOS Inc. announced that it has received CAD 4.001179 million in fundingOn December 9, 2025, DIAGNOS Inc. closed the transaction. The company announced that it has issued 13,337,262 Units at a price of CAD 0.30 per Unit for aggregate gross proceeds of CAD 4,001,178.60. The transaction is oversubscribed. In connection with the Offering, the Company paid a cash commission of CAD 153,974.40, issued 666,863 Units as a corporate finance fee and issued 513,248 broker warrants (the “Broker Warrants”). Each Broker Warrant entitles the holder to acquire a Unit at the Issue Price at any time on or before June 6, 2027. The securities to be issued under the Offering will have a hold period of four months and one day from the Closing Date under applicable Canadian securities laws. Certain related parties of the Company, namely two (2) directors and one (1) officer, participated in the Offering, acquiring an aggregate of 316,665 Units on the same basis as other subscribers. The transaction is oversubscribed.
お知らせ • Nov 11DIAGNOS Inc. announced that it expects to receive CAD 2 million in fundingDIAGNOS Inc. announces a brokered private placement to issue 6,666,667 units at a price of CAD 0.30 per unit for gross proceeds of CAD 2,000,000.1 on November 10, 2025. Each Unit shall consist of one common share in the capital of the Company and one common share purchase warrant. Each Warrant shall be exercisable into one additional common share of the Company at a price of CAD 0.40 per Warrant Share at any time for a period of 18 months following the Closing Date. The Offering is expected to close on or around December 3, 2025, or such other dates as agreed upon between the Company and the Lead Agent and is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the Offering will have a hold period of four months and one day from the Closing Date under applicable Canadian securities laws.
お知らせ • Nov 01Diagnos Inc. Announces the Appointment of Dr. Philipgpe Couillard as Chairman of the Board of DirectorsDiagnos Inc. announced the appointment of Dr. Philipgpe Couillard as Chairman of the board of directors (the “Board”).Dr. Couillard is a seasoned business advisor and neurosurgeon. He has served in two significant public roles in the government of the province of Quebec (Canada); as Minister of Health and Social Services between 2003 and 2008 and as Premier of the province from 2014 to 2018. Dr. Couillard joined the Board of DIAGNOS on April 1, 2024.
お知らせ • Oct 28DIAGNOS Inc. Announces Dr. Pierre-Luc Charlebois Joins Advisory BoardDIAGNOS Inc. announced that Dr. Pierre-Luc Charlebois has joined the Corporation’s Advisory Board. Along with fellow members, Dr. Tomas J. Philipson, former vice chairman of the White House Council of Economic Advisers, Mr. Ed Weiner, a seasoned entrepreneur, and Dr. Barry A. Ginsberg, optometrist, Dr. Charlebois will act as special counsel to the Corporation’s management. Dr. Charlebois is an orthopedic surgeon practicing in the province of Quebec, Canada. Dr. Charlebois earned his orthopedic surgeon medical degree from the University of Montreal. He also holds a master`s degree in Health Economics, Policy and Management from the London School of Economics and Political Science.
お知らせ • Sep 06DIAGNOS Inc. announced that it has received CAD 0.1 million in fundingOn September 5, 2025, DIAGNOS Inc. closed the transaction. The company issued 10 units at a price of CAD 10,000 per unit for gross proceeds of CAD 100,000. Each unit consists of one CAD 10,000 unsecured convertible debenture and 10,000 stock warrants. The units have been subscribed by one director of the corporation. Each debenture has a term of 12 months and bears interest at the annual rate of 10%, payable in cash. At the option of the holder of the debenture, the principal amount may be converted, at any time during the term, into common shares of the corporation at a price of CAD 0.28 per share. Each warrant entitles the holder to purchase one share at a price of CAD 0.40 per share, at any time during the term. All securities to be issued as part of the private placement are subject to a statutory hold period ending on January 6, 2026. The private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation.
お知らせ • Sep 04DIAGNOS Inc. announced that it expects to receive CAD 0.1 million in fundingDIAGNOS Inc. announces a non-brokered private placement to issue 10 units at a price of CAD 10,000 per unit for gross proceeds of CAD 100,000 on September 3, 2025. Each unit consists of One CAD 10,000 unsecured convertible debenture and 10,000 stock warrants. Each Debenture has a term of 12 months and bears interest at the annual rate of 10%, payable in cash. At the option of the holder of the Debenture, the principal amount may be converted, at any time during the Term, into common shares of the Corporation at a price of CAD 0.28 per Share. One director of the Corporation has committed to subscribe for all of the Units of the Private placement. All securities to be issued as part of the Private placement will be subject to a 4-month statutory hold period. The Private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation.
お知らせ • Jul 28DIAGNOS Inc., Annual General Meeting, Sep 25, 2025DIAGNOS Inc., Annual General Meeting, Sep 25, 2025. Location: quebec, brossard Canada
お知らせ • Jun 26DIAGNOS Inc. Announces Dr. Barry A. Ginsberg Joins Advisory BoardDiagnos Inc. announced that Dr. Barry A. Ginsberg, O.D. has joined the Corporation's Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers and Mr. Ed Weiner, a seasoned entrepreneur, to provide valuable insights to DIAGNOS about the US optical market. Dr. Ginsberg brings more than three decades of practice across corporate, retail and private-practice settings, giving him a ground-level view of how new technologies gain traction in high-volume optometry environments. He has repeatedly identified and launched innovative products and services that increased revenue per visit and improved patient retention for leading optical chains. This commercial experience, combined with his expertise in advanced contact-lens fitting and ocular-disease management, will help DIAGNOS refine its go-to-market strategy and demonstrate the tangible ROI of AI-driven screening to investors and practitioners alike. Dr. Ginsberg earned a B.A. in Chemistry with a minor in Economics from Yeshiva University, followed by a B.S. and Doctor of Optometry from the Pennsylvania College of Optometry. His training included an externship at the Feinbloom Low Vision Center in Philadelphia, where he focused on age-related macular degeneration, and another at the Goldschleger Eye Institute in Tel Hashomer Hospital, Israel, where he concentrated on glaucoma and other ocular diseases.
お知らせ • Jun 11Diagnos Appoints Ed Weiner, to Its Advisory Board for the United StatesDiagnos Inc. announced that Mr. Ed Weiner has joined the Corporation’s Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers, to provide valuable insights to DIAGNOS about the US optical market. Mr. Weiner is a seasoned entrepreneur and has been a leader in the optical industry for decades. He was the first to introduce Ralph Lauren Eyewear. He also partnered with Walmart to open 400 optical locations within Walmart’s chain of stores. Mr. Weiner was also chairman and founder of National Vision Associates, one of the largest optical retailers in the USA.
お知らせ • Jun 05Diagnos Inc. Announces That Tomas J. Philipson Joins the Corporation's Advisory BoardDiagnos Inc. announced that Dr. Tomas J. Philipson has joined the Corporation’s Advisory Board. Dr. Tomas J. Philipson is considered an expert in US economic policy, particularly health care policy and appears often on major media outlets, including Forbes, The Economist, The Wall Street Journal, The New York Times, CNN, BBC, CBS, ABC, CNBC, Fox News, Fox Business, Newsmax, Yahoo Finance, American Voice, Bloomberg, and CSPAN. He currently serves as Managing Partner of the VC firm MEDA Ventures, serves on several corporate boards, and has co-founded several companies, including Precision Health Economics LLC, with an exit in 2015 (currently owned by Blackstone). His government service includes a full-time position as vice chairman and acting chairman of the White House Council of Economic Advisers 2017-20. He previously served as a senior economic adviser to the head of the Food and Drug Administration (FDA) and a senior economic advisor to the head of the Centers for Medicare and Medicaid Services (CMS). Dr. Philipson was appointed to the Key Indicator Commission by the Speaker of the House of Representatives in 2012. He was a scientific advisor to the House of Representatives initiative 21st Century Cures in 2015 and The Biden Cancer Initiative in 2017. He served as a healthcare advisor to Senator John McCain's 2008 presidential campaign. He received numerous worldwide research awards while he was a chaired professor at the University of Chicago. He is a two-time winner of the Arrow Award of The International Health Economics Association, the highest honor in health economics. Other awards include the Garfield Award for Economic Research, the Prêmio Haralambos Simeonidis from the Brazilian Economic Association, and the Milken Institute’s Distinguished Economic Research Award. He received a B.A. in mathematics from Uppsala University in Sweden, an MA in Mathematics from Claremont Graduate School, and an MA and Ph.D. in Economics from the Wharton School and the University of Pennsylvania.
お知らせ • Apr 09Diagnos Inc. Provides Update on its Health Canada Medical Device License ApplicationDIAGNOS Inc. provided an update on the progress of its Medical device license application for CARA System, submitted to Health Canada in early September 2024. Following the submission of its application in early September, DIAGNOS has engaged in ongoing communication with Health Canada, providing timely responses to all regulatory requests. After more than 11 proactive inquiries regarding the application's status, the company announced that Health Canada has confirmed that the application is now under "active processing", having progressed from a previous backlog.
お知らせ • Feb 26DIAGNOS Inc. to File for FDA Pre-Market Authorization of Its AI-Powered Cara SystemDiagnos Inc. announced that it is officially filing for U.S. Food and Drug Administration (FDA) pre-market authorization of its CARA SYSTEM, a machine-learning-enabled medical device (MLMD). To ensure a smooth regulatory process, DIAGNOS has engaged ORA, a leading clinical research organization specializing in regulatory affairs and clinical development for ophthalmic products. The CARA SYSTEM is designed to assist optometrists and frontline healthcare professionals in analyzing fundus images for the early detection of diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy. By leveraging Artificial Intelligence, DIAGNOS aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.
お知らせ • Feb 06DIAGNOS Inc. announced that it has received CAD 2.014611 million in fundingDIAGNOS Inc. announced a non-brokered private placement to issue 6,715,370 units at a price of CAD 0.30 per unit for gross proceeds of CAD 2,014,611 on February 5, 2025. Each Unit consists of one common share and one common share warrant. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending August 5, 2026. In connection with the closing of the Private Placement, the Corporation paid cash commissions totaling CAD 39,246.72 and issued an aggregate number of 130,821 finder’s warrants to five qualified firms acting at arm’s length to the Corporation. Each finder’s warrant entitles the holder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending August 5, 2026. All securities issued as part of the Private Placement are subject to a statutory hold period ending June 6, 2025. The closing of the Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.